A novel 8-gene panel for prediction of early biochemical recurrence in patients with prostate cancer after radical prostatectomy

Guo, Jinan1,2; Zhao, Chenhui3; Zhang, Xinzhou4; Wan, Zhong5; Chen, Tingting6; Miao, Jiashun6; Cai, Jinping6; Xie, Wenchuan6; Chen, Hao6; Huang, Mengli6; Zhao, Xiaochen6; Wei, Wei7; Shen, Qi8

2022

American Journal of Cancer Research   Impact Factor & Quartile

2156-6976

Approximately 25% of prostate cancer (PCa) cases experience biochemical recurrence (BCR) following radical prostatectomy (RP). The patients with BCR, especially with BCR <= 2 year after RP (early BCR), are more likely to develop clinical metastasis and castration resistance. Now decision-making regarding BCR after RP relies solely on clinical parameters. We thus attempted to establish an early BCR-risk prediction model by combining a molecular signature with clinicopathological features for guiding clinical decision-making. In this study, an 8-gene signature was derived, and these eight genes were SPTBN2, LGI3, TGM3, LENG9, HAS3, SLC25A27, PCDHGA1, and ADPRHL1. The Kaplan-Meier analysis revealed a significantly prolonged BCR-free survival in the patients with low-risk scores compared to those with high-risk scores in both training and validation datasets. Harrell's concordance index and time-dependent receiver operating characteristic analysis demonstrated that this gene signature tended to outperform three commercial panels at early BCR prediction. Moreover, this signature was also proven as an independent predictor of BCR-free survival. A nomogram, incorporating the gene signature and clinicopathologic features, was constructed and excellently predicted 1-, 2- and 3-year BCR-free survival of localized PCa patients after RP. Gene set enrichment analysis, tumor immunity, and mRNA expression profiling analysis showed that the high-risk group was more prone to the immunosuppressive microenvironment and impaired DNA damage response than the low-risk group. Collectively, we successfully developed a novel 8-gene signature as a powerful predictor for early BCR after RP and created a prognostic nomogram, which may help inform the clinical management of PCa.

Prostate cancer biochemical recurrence gene signature risk stratification biochemical recurrence-free survival

SCI

English

First ; Corresponding

Oncology

Oncology

WOS:000844511700027

E-CENTURY PUBLISHING CORP

Web of Science

1.South Univ Sci & Technol China, Affiliated Hosp 1, Shenzhen Peoples Hosp, Jinan Univ,Clin Med Coll 2,Dept Urol, Shenzhen, Peoples R China
2.Shenzhen Urol Minimally Invas Engn Ctr, Shenzhen, Peoples R China
3.Shanghai Jiao Tong Univ, Ruijin Hosp, Lu Wan Branch, Sch Med, Shanghai, Peoples R China
4.South Univ Sci & Technol China, Affiliated Hosp 1, Shenzhen Peoples Hosp,Dept Nephrol, Jinan Univ,Clin Med Coll 2,Shenzhen Key Lab Kinde, Shenzhen, Peoples R China
5.Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai, Peoples R China
6.3D Med Inc, Shanghai, Peoples R China
7.Univ Chinese Acad Sci, Hwa Mei Hosp, Dept Urol, Northwest St 41, Ningbo 315000, Zhejiang, Peoples R China
8.South Univ Sci & Technol China, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Hematol,Jinan Univ,Affiliated Hosp 1, 1017 Dongmen North Rd, Shenzhen 518000, Peoples R China

Guo, Jinan,Zhao, Chenhui,Zhang, Xinzhou,et al. A novel 8-gene panel for prediction of early biochemical recurrence in patients with prostate cancer after radical prostatectomy[J]. American Journal of Cancer Research,2022,12(7).

Guo, Jinan.,Zhao, Chenhui.,Zhang, Xinzhou.,Wan, Zhong.,Chen, Tingting.,...&Shen, Qi.(2022).A novel 8-gene panel for prediction of early biochemical recurrence in patients with prostate cancer after radical prostatectomy.American Journal of Cancer Research,12(7).

Guo, Jinan,et al."A novel 8-gene panel for prediction of early biochemical recurrence in patients with prostate cancer after radical prostatectomy".American Journal of Cancer Research 12.7(2022).